Glenmark Pharmaceuticals Inc., USA Launches Authorized Generic of INLYTA® Tablets, 1 mg and 5 mg

HealthK Puspa16 Nov 2026

Elmwood Park, New Jersey, Nov 16: Glenmark Pharmaceuticals Inc., today announced the launch of Axitinib Tablets, 1 mg and 5 mg. This product is an  Authorized Generic version of INLYTA®1 tablets. 

According to IQVIA® sales data for the 12-month period ending September 2026, U.S. annual  sales of INLYTA® Tablets were approximately $538.4 million. 

“The launch of Axitinib Tablets reinforces Glenmark’s commitment to expanding access to  quality, affordable medicines for patients in the United States,” said Marc Kikuchi, President  & Business Head, North America. By adding this important product to our portfolio, we  continue to strengthen our focus on addressing the evolving needs of patients and healthcare  providers.”